EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD – A Post-hoc Analysis of the WIL-31 Study

Ana Boban, Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat, Robert F Sidonio

Clinical and Applied Thrombosis/Hemostasis · 2024

DOI: 10.1177/10760296241306755 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Ana Boban und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: Epistaxis, von Willebrand Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Octapharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prophylaxis with a von Willebrand factor (VWF) concentrate is recommended in von Willebrand disease (VWD) patients with a history of frequent and severe bleeds. Despite nosebleeds being a frequent manifestation of VWD, few studies have investigated the efficacy of factor prophylaxis in preventing nosebleeds in patients with severe VWD.

Methods

This post-hoc analysis of a prospective, 12-month, phase 3 study assessed the efficacy of wilate in the prevention of nosebleeds in 33 patients aged ≥6 years with severe type 1, type 2 or type 3 VWD. All patients previously participated in a 6-month prospective study of on-demand treatment with any VWF concentrate. Prophylactic efficacy was assessed by comparing total and spontaneous annualized bleeding rates for nosebleeds (TABR and SABR, respectively) during prophylaxis with rates during on-demand treatment.

Results

The mean TABR and SABR for nosebleeds were reduced by 76% and 81% respectively during prophylaxis versus on-demand treatment (2.7 vs 11.0 and 2.1 vs 10.9). During the second 6 months of prophylaxis, mean TABR was 49% lower and mean SABR 57% lower versus the first 6 months. The percentage of patients with zero nosebleeds was 19% during 6 months of on-demand treatment, 55% during the first 6 months of prophylaxis, and 68% during the second 6 months of prophylaxis. The efficacy of wilate in the treatment of breakthrough nosebleeds was rated excellent in 99% of cases.

Conclusion

This post-hoc analysis demonstrated the efficacy of wilate prophylaxis in the prevention and treatment of nosebleeds in children and adults with severe VWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epistaxisvon Willebrand DiseasesHumansMaleFemaleAdultAdolescentMiddle AgedProspective StudiesChildvon Willebrand FactorYoung AdultAged

Stichwörter der Autor:innen

epistaxisfactor VIIIprophylaxisvon Willebrand diseasevon Willebrand factor

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
  • Zagreb University School of Medicine, Zagreb, Croatia.
  • Communal Nonprofit Enterprise "Western Ukrainian Specialized Children's Medical Center" of Lviv Regional Council, Lviv, Ukraine.
  • Hemostasis Pathology Center, National Specialized Children's Hospital Okhmatdyt, Kyiv, Ukraine.
  • Department of Pediatric Hematology Oncology, Nini Hospital, Tripoli, Lebanon.
  • University of Balamand School of Medicine and Medical Sciences, Balamand, Lebanon.

Förderung

  • Octapharma

Zitieren

APA

Boban, A., Dubey, L., Vilchevska, K. V., Inati, A., Khayat, C. D., & Sidonio, R. F. (2024). Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD – A Post-hoc Analysis of the WIL-31 Study. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241306755

Vancouver

Boban A, Dubey L, Vilchevska KV, Inati A, Khayat CD, Sidonio RF. Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD – A Post-hoc Analysis of the WIL-31 Study. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241306755

BibTeX
@article{Boban2024,
  author = {Boban, Ana and Dubey, Leonid and Vilchevska, Kateryna V and Inati, Adlette and Khayat, Claudia Djambas and Sidonio, Robert F},
  title = {Efficacy of Wilate Prophylaxis in Reducing Nosebleeds in Patients with Severe VWD – A Post-hoc Analysis of the WIL-31 Study},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2024},
  doi = {10.1177/10760296241306755}
}
Kostenlos starten →